INVO Bioscience Reports First Quarter 2022 Financial Results

May 16, 2022 | Press Releases

Company to Host Conference Call Today at 4:30pm ET SARASOTA, Fla., May 16, 2022 — INVO Bioscience, Inc. (Nasdaq: INVO) (“INVO” or the “Company”), a commercial-stage fertility company focused on expanding access to advanced treatment...

INVO Bioscience to Report First Quarter 2022 Financial Results on Monday, May 16, 2022

May 9, 2022 | Press Releases

Financial results to be released after market close; Conference call to be conducted at 4:30 pm ET SARASOTA, Fla., May 9, 2022 — INVO Bioscience, Inc. (NASDAQ: INVO), a commercial-stage fertility company focused on expanding access to advanced treatment...

INVO Celebrates National Infertility Awareness Week at the INVO Center in Atlanta, Georgia

Apr 28, 2022 | Press Releases

Bloom Fertility, an INVO Center to grant three eligible patients a full IVC treatment cycle SARASOTA, Fla., April 28, 2022 — INVO Bioscience, Inc. (NASDAQ: INVO), a commercial-stage fertility company focused on expanding access to advanced treatment worldwide...

INVO Selects Kansas City as additional INVO Center Location

Apr 14, 2022 | Press Releases

U.S. Market Expansion Continues as Planned SARASOTA, Fla., April 14, 2022 — INVO Bioscience, Inc. (NASDAQ: INVO) (“INVO” or the “Company”), a commercial-stage fertility company focused on expanding access to advanced treatment worldwide...

INVO Bioscience to Participate in the Lytham Partners Spring 2022 Investor Conference

Apr 4, 2022 | Press Releases

SARASOTA, Fla., April 4, 2022 — INVO Bioscience, Inc. (NASDAQ: INVO), a commercial-stage fertility company focused on expanding access to advanced treatment worldwide with its INVOcell® medical device and the intravaginal culture (“IVC”)...